NO20082127L - Antagonister mot interaksjon av PF4 og Rantes - Google Patents

Antagonister mot interaksjon av PF4 og Rantes

Info

Publication number
NO20082127L
NO20082127L NO20082127A NO20082127A NO20082127L NO 20082127 L NO20082127 L NO 20082127L NO 20082127 A NO20082127 A NO 20082127A NO 20082127 A NO20082127 A NO 20082127A NO 20082127 L NO20082127 L NO 20082127L
Authority
NO
Norway
Prior art keywords
rantes
interaction
antagonists against
antagonists
recruitment
Prior art date
Application number
NO20082127A
Other languages
English (en)
Norwegian (no)
Inventor
Christian Weber
Philipp Von Hundelshausen
Rory Koenen
Original Assignee
Rwth Aachen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rwth Aachen filed Critical Rwth Aachen
Publication of NO20082127L publication Critical patent/NO20082127L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
NO20082127A 2005-10-14 2008-05-06 Antagonister mot interaksjon av PF4 og Rantes NO20082127L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005049637A DE102005049637A1 (de) 2005-10-14 2005-10-14 Antagonisten gegen die Interaktion von PF4 und RANTES
PCT/EP2006/009790 WO2007042263A1 (de) 2005-10-14 2006-10-11 Antagonisten gegen die interaktion von pf4 und rantes

Publications (1)

Publication Number Publication Date
NO20082127L true NO20082127L (no) 2008-07-08

Family

ID=37670863

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082127A NO20082127L (no) 2005-10-14 2008-05-06 Antagonister mot interaksjon av PF4 og Rantes

Country Status (17)

Country Link
US (2) US8110552B2 (ko)
EP (2) EP1934249A1 (ko)
JP (1) JP5385611B2 (ko)
KR (1) KR101477767B1 (ko)
CN (2) CN102911260A (ko)
AU (1) AU2006301494B2 (ko)
BR (1) BRPI0617384A2 (ko)
CA (1) CA2648649A1 (ko)
DE (1) DE102005049637A1 (ko)
EA (1) EA013508B1 (ko)
ES (1) ES2546094T3 (ko)
HK (1) HK1127069A1 (ko)
IL (1) IL190820A0 (ko)
MX (1) MX2008004866A (ko)
NO (1) NO20082127L (ko)
WO (1) WO2007042263A1 (ko)
ZA (1) ZA200804081B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005049637A1 (de) 2005-10-14 2007-04-26 Rheinisch-Westfälische Technische Hochschule Aachen Antagonisten gegen die Interaktion von PF4 und RANTES
CA2737924A1 (en) * 2008-10-06 2010-04-15 Joshua Robert Schultz Methods of treating inflammation
WO2011116245A2 (en) * 2010-03-19 2011-09-22 Carolus Therapeutics, Inc. Methods of treating inflammation
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
US11402391B2 (en) 2020-12-21 2022-08-02 Incelldx, Inc. Methods of treating a long-hauler subject for chronic COVID-19 by administering a CCR5 or CCL5 antagonist

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006751A1 (en) * 1996-08-16 1998-02-19 Research Corporation Technologies, Inc. Mcp-3, rantes and mip-1alpha receptor antagonists
US6168784B1 (en) * 1997-09-03 2001-01-02 Gryphon Sciences N-terminal modifications of RANTES and methods of use
EP0906954A1 (en) * 1997-09-29 1999-04-07 Applied Research Systems ARS Holding N.V. Amino-terminal truncated c-c chemokines as chemokine antagonist
AU1616499A (en) * 1997-12-01 1999-06-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chemokine variants and methods of use
IT1303736B1 (it) * 1998-11-11 2001-02-23 San Raffaele Centro Fond Peptidi derivati da rantes con attivita' anti-hiv.
DE10014516A1 (de) 2000-03-23 2001-09-27 Weber Christian Antagonisten des RANTES Rezeptors CCR1 zur Prävention und Therapie der Atherosklerose und Restenose
ITMI20030107A1 (it) * 2003-01-24 2004-07-25 Primm Srl Peptidi derivati da rantes.
DE102005049637A1 (de) 2005-10-14 2007-04-26 Rheinisch-Westfälische Technische Hochschule Aachen Antagonisten gegen die Interaktion von PF4 und RANTES
CA2737924A1 (en) * 2008-10-06 2010-04-15 Joshua Robert Schultz Methods of treating inflammation

Also Published As

Publication number Publication date
US20120077733A1 (en) 2012-03-29
CA2648649A1 (en) 2007-04-19
CN102911260A (zh) 2013-02-06
DE102005049637A1 (de) 2007-04-26
EA200801077A1 (ru) 2008-12-30
AU2006301494B2 (en) 2011-01-06
US20080287652A1 (en) 2008-11-20
JP2009511029A (ja) 2009-03-19
HK1127069A1 (en) 2009-09-18
EP1934249A1 (de) 2008-06-25
WO2007042263A1 (de) 2007-04-19
AU2006301494A1 (en) 2007-04-19
CN101356190B (zh) 2012-11-14
BRPI0617384A2 (pt) 2011-07-26
KR101477767B1 (ko) 2015-01-02
IL190820A0 (en) 2008-11-03
EA013508B1 (ru) 2010-06-30
JP5385611B2 (ja) 2014-01-08
ZA200804081B (en) 2009-11-25
ES2546094T3 (es) 2015-09-18
MX2008004866A (es) 2008-10-20
EP2363412A1 (de) 2011-09-07
US8110552B2 (en) 2012-02-07
EP2363412B1 (de) 2015-06-10
KR20080080093A (ko) 2008-09-02
CN101356190A (zh) 2009-01-28
US8501680B2 (en) 2013-08-06

Similar Documents

Publication Publication Date Title
CY1118222T1 (el) Συνθεσεις λυασης φαινυλαλανινης αμμωνιας προκαρυωτικων και μεθοδοι αγωγης καρκινου χρησιμοποιωντας συνθεσεις εξ' αυτης
TW200744642A (en) Novel peptides for use in the treatment of obesity
EA200800564A1 (ru) Производные ксантина как селективные агонисты нм74а
ATE466085T1 (de) Protease-resistente modifizierte interferon alpha polypeptide
BRPI0517621A (pt) sais hidroxibenzoato de compostos de metanicotina
TW200634003A (en) Chemical compounds
TW200616974A (en) Chemical compounds
ATE365213T1 (de) Aminosäuresequenzen die die fähigkeit besitzen, die durchdringung durch eine biologische barriere erleichtern
NO20085064L (no) 4,5-difenyl-pyrimidinyl-oksy eller -merkaptosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
NZ617196A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
GEP20125565B (en) Lactam compounds and their pharmaceutical use
NO20055649L (no) Substituert dihydrokinazolin med antiviale egenskaper
TW200635899A (en) Chemical compounds
RS20050361A (en) Novel medicament for the treatment of chronic obstructive pulmonary diseases
MY138708A (en) Biaryloxymethylarenecarboxylic acids
NO20073830L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
NO20082127L (no) Antagonister mot interaksjon av PF4 og Rantes
PL1620425T3 (pl) Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu
CY1114724T1 (el) Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων
UA86399C2 (ru) Применение 2,5 дигидроксибензолсульфоновой кислоты для изготовления лекарства, которые применяют для лечения болезней, зависимых от ангиогенеза
ATE380188T1 (de) Substituierte chinolone
ATE443722T1 (de) Peptide und peptidderivate, ihre herstellung sowie ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung
JP2011528334A5 (ko)
NO20083583L (no) Heterosykliske antivirale forbindelser
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application